Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity…
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 41 companies made new 52-week lows.
FDA Clears LPCN 2101 IND For Adult Epilepsy Treatment
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders with high unmet medical needs, announced
LPCN: First Quarter 2022 Financial and Operational Results
By John Vandermosten, CFA
NASDAQ:LPCN
READ THE FULL LPCN RESEARCH REPORT
36 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday.
Antares Pharma’s Oral Testosterone Treatment Scores FDA Approval
Antares Pharma Inc (NASDAQ:ATRS) has nabbed another FDA approval, and the Company’s second involving testosterone. The Company announced FDA approval…
Lipocine Press Release Confirms Partner Antares Pharma Received FDA Approval For TLANDO
Commercial launch expected in 2Q 2022
SALT LAKE CITY, March 29, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products forCommercial launch expected in 2Q 2022
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.